ABL Tyrosine Kinase
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
... ABL tyrosine kinase inhibitor (TKI) therapy has improved the survival of patients with Philadelphia (Ph) chromosome-positive ...However, ABL TKIs cannot eradicate leukemia stem ...an ...
11
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
... protein kinase structures in the Protein Data Bank ...protein kinase family allows one to see how small changes in the primary structure, even those remote from the ATP-binding site, can be exploited to ...
6
Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
... ABL kinase domain mutation can be crucial in directing therapy in the CML patient with resistance to first or second generation ...baseline ABL kinase domain mutations except when T315I and ...
6
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
... Abstract: Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and outcomes of chronic myeloid leukemia (CML). Despite their significant impact on the management of CML, there is growing ...
11
Nilotinib A New FDA Approved Drug for the Treatment of Chronic Myelogenous Leukaemia
... - ABL fusion protein has been found to be present in more than 90% of CML ...BCR-ABL tyrosine kinase that would be effective in patients with Imatinib-resistant ...the kinase domain of ...
7
Bcr Abl regulates osteopontin transcription via Ras, PI 3K, aPKC, Raf 1 and MEK
... phosphatidylinositol-3 kinase, atypical protein kinase C, Raf-1, and mitogen-activated protein kinase kinase, leading to the ultimate ex- pression of ...
12
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
... (PDGFR)/Abelson tyrosine kinase (Abl) inhibitor ...and Abl protein levels were elevated in the LTED cells compared to wild type (wt)-MCF7 ...PDGF/Abl tyrosine kinase ...
15
Applying the discovery of the Philadelphia chromosome
... BCR-ABL tyrosine kinase causes ...BCR-ABL kinase. Incorporating the use of markers of BCR-ABL kinase inhibition into clinical trials led to the realization that ...
9
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
... BCR-ABL tyrosine kinase inhibitors (TKIs) have improved outcomes for patients diagnosed with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic ...
8
Distinct Transforming Activity of ABL Family Tyrosine Kinase Oncogenes Is Induced by Their C Terminal Domain*
... ARG kinase activity in TEL/ARG is inhibited by the ABL tyrosine kinase inhibitor (TKI) STI571 ...of tyrosine kinases, espe- cially if the cell lines were selected for certain ...
11
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
... Bcr-Abl tyrosine kinase activity in cell lines and that it is at least 10-to 30-fold more potent than imatinib in inhibiting proliferation of Bcr-Abl-expressing ...
7
BCR ABL kinase is dead; long live the CML stem cell
... fusion tyrosine kinase BCR-ABL. Tyrosine kinase inhibitor (TKI) therapy has led to long-term remissions, but patients remain BCR-ABL + ...BCR-ABL kinase inhibition ...
5
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
... the understanding of the molecular defect underlying the pathogenesis of CML, and they all target the bcr-abl tyrosine kinase. The different TKIs are distinguished by their rela- tive affinities for ...
9
A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo
... activated tyrosine ki- nase that causes human chronic myelogenous ...of ABL, thereby activating ABL tyrosine kinase ...if ABL was dimerized through other mechanisms, activation ...
9
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
... Bcr-Abl tyrosine kinase inhibitors (TKI), such as nilotinib (AMN107, Tasigna; Novartis, Basel, Switzerland) and bosutinib (SKI-606; Wyeth, Madison, NJ) represent the newer generation of TKIs which ...
12
Targeted therapy: resistance and re-sensitization
... lymphoma kinase (ALK) EGFR represents a member of the cell surface receptor tyrosine kinase (RTK) molecular family, and it is activated upon ligand binding as well as receptor ...receptor ...
6
3939.full.pdf
... the kinase mTOR (known as mammalian target of rapamycin) integrates environmental cues provided by nutrients, cytokines, and costimulatory sig- nals present in the immune microenvironment and helps to promote Th ...
10
Molecular signatures of chronic myeloid leukemia stem cells
... Adhesion molecules such as P-selectin (encoded by the Selp gene) are essential for normal hematopoiesis, and their dysregulation has been linked to leukemogenesis [34-36]. Like HSCs, LSCs depend upon their microenvi- ...
6
Effects of The BCR-ABLl Oncogene on DNA Damage and Repair
... Importantly, both DKO and DBA cells show error prone DNA repair after IR as demonstrated by SKY. SKY analysis suggests that BCR-ABL does not cause a greater increase in chromosomal abnormalities after IR and ...
140
Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
... TKI: tyrosine kinase inhibitor; Abl: Abelson; CP: chronic phase; CML: chronic myeloid leukemia; BELA: Bosutinib Efficacy and Safety in Newly Diagnosed CML; BFORE: First-line chrOnic my[r] ...
8